Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage

2 Aug 2024

Abstract excerpt

Schoenfeld and colleagues report, in this issue, a measurable objective response rate in 6/28 (21.4%) of patients with advanced non-small cell lung cancer treated with lifileucel, a cell therapy product based on autologous tumor-infiltrating lymphocytes (TIL). Extending solid evidence in advanced melanoma that led to FDA approval of lifileucel, this new evidence bodes well for treating patients with other common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to CAR-T cell therapy research
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39091204
DOI: 10.1158/2159-8290.cd-24-0645

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center StagePMID 39091204Read ↗

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.Semantic proximity Read ↗

Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) TherapySemantic proximity Read ↗

Phenotypic analysis of tumor-infiltrating lymphocytes from non-small cell lung cancer and their potential application for adoptive cell therapy.Semantic proximity Read ↗

Characteristics and Developmental Trajectory of Clinical Trials Focused on Tumor-Infiltrating Lymphocytes for Cancer TreatmentSemantic proximity Read ↗

Expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer: Clinical potential and efficacy in EGFR mutation subsets.Semantic proximity Read ↗

Autologous Cytokine-Induced Killer (CIK) Cell Immunotherapy plus Sintilimab and Chemotherapy in Advanced Non‒Small-Cell Lung Cancer: 3-Year Outcomes From the Phase Ib CCICC-002a StudySemantic proximity Read ↗

Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatmentsSemantic proximity Read ↗

IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.Semantic proximity Read ↗

Prospects for Combined Treatment of Non-Small Cell Lung Cancer Using Autologous Activated LymphocytesSemantic proximity Read ↗

Harnessing the lymphocyte meta-phenotype to optimize adoptive cell therapySemantic proximity Read ↗

GX-I7(rhIL-7-hyFc, efineptakin alfa), a long-acting IL-7, safely and effectively increased peripheral CD8<sup>+</sup>and CD4<sup>+</sup>T cells and TILs in patients with solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.